Addressing The Silent Epidemic The Growing Prevalence Of Chronic Kidney Disease Fuels Expansion In The Nephrology Drugs Market Driving Nephrology Drugs Market Growth: A Future-Defining Shift for 2025-2034

 The Business Research Company’s report on the Nephrology Drugs Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.

 
 What are the primary drivers fueling the growth of the nephrology drugs market in recent years?
 The rising prevalence of chronic kidney disease is expected to propel the growth of the nephrology drugs market going forward. Chronic kidney disease (CKD) refers to damaged kidneys that are unable to filter blood as effectively as they should. because kidney damage develops gradually over a lengthy period of time. Wastes could accumulate in the body as a result of this injury. Nephrology drugs are primarily used in the treatment of chronic kidney disease to enhance kidney function and slow the disease, preventing it from doing more harm to the body, so these factors boost the nephrology drug market. For instance, in July 2022, according to reports shared by the Centers for Disease Control and Prevention (CDC), a US-based health protection agency, it was estimated that in the US, more than 37 million people were diagnosed with chronic kidney disease, which is more common in people aged 65 years or older (38 percent). Furthermore, according to the Kidney Foundation of Canada, a Canada-based non-profit organization, 4 million Canadians are suffering from kidney diseases. 35 percent of diabetic patients are the leading cause of kidney failure. These numbers are expected to rise in the future. Therefore, the rising prevalence of chronic kidney disease is driving the growth of the nephrology drug market.
 
 Access Your Free Sample of the Global Nephrology Drugs Market Report — Get Insights Now!
 https://www.thebusinessresearchcompany.com/sample.aspx?id=10076&type=smp
 
 What is the projected market size of the nephrology drugs industry, and how is it expected to grow?
 The nephrology drugs market size has grown strongly in recent years. It will grow from$16.88 billion in 2024 to $17.86 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to rising prevalence of chronic kidney diseases (CKD), advancements in drug development, increasing awareness and diagnosis, government initiatives and healthcare policies, increasing incidence of diabetes
 
 The nephrology drugs market size is expected to see strong growth in the next few years. It will grow to “$23.04 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to emerging therapies and drug innovations, precision medicine and personalized treatment approaches, increasing healthcare expenditure, telehealth and remote patient monitoring, global health initiatives. Major trends in the forecast period include collaborations and partnerships, technological advancements in dialysis, advancements in treatment modalities, growing emphasis on early diagnosis and intervention, technological integration in nephrology management.
 
 Gain Exclusive Market Insights — Customize Your Research Report Today For Fast Delivery!
 https://www.thebusinessresearchcompany.com/customise?id=10076&type=smp
 
 Who are the key players driving competition in the nephrology drugs market?
 Major companies operating in the nephrology drugs market include AstraZeneca plc, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., F. Hoffmann-La Roche AG, FibroGen Inc., Johnson And Johnson, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Reata Pharmaceuticals Inc., Ardelyx Inc., Novo Nordisk A/S, Novartis AG, Baxter International Inc., Bristol Myers Squibb Company, Kissei Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals, OPKO Health Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vifor Pharma Group, Bayer AG, Amicus Therapeutics, Chugai Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Mylan N.V., Endo Pharmaceuticals plc
 
 What key trends are expected to drive the natural gas generator market during the forecast period?
 Product innovation is a key trend gaining popularity in the nephrology drug market. Major companies operating in the nephrology drug market are innovating new products and drugs to sustain their position in the market. For instance, in March 2022, Zydus Lifesciences Limited., an Indian-based pharmaceutical company, launched Oxemia (desidustat) for chronic kidney disease (CKD). It is an oral, small-molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor with a convenient therapeutic option for the treatment of anemia. And approved by the Drug Controller General of India. in Phase III clinical trials It demonstrated good safety profiles, hepcidin downregulation, better iron mobilization, and a reduction in LDL-C in chronic kidney disease patients. Also, by providing treatment at a reasonable price and enhancing patients quality of life, this will lessen the burden of disease.
 
 Which key geographies are driving the growth of the nephrology drugs market?
 North America was the largest region in the nephrology drug market in 2024.Europe will be the second-largest growing region in the nephrology drug market in 2024. The regions covered in the nephrology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
 
 Order Your Report Now For Swift Delivery
 https://www.thebusinessresearchcompany.com/report/nephrology-drugs-global-market-report
 
 What are the key segments driving growth in the nephrology drugs market?
 The nephrology drugs market covered in this report is segmented –
 
 1) By Drugs: Antihypertensive Agents, Erythropoiesis-Stimulating Agents, Diuretics, ACE Inhibitors, Antidiabetic Agents, Other Drugs
 2) By Route Of Administration: Oral, Parenteral, Other Route Of Administration
 3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
 4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
 
 Subsegments:
 1) By Antihypertensive Agents: Calcium Channel Blockers, Beta-Blockers, Angiotensin II Receptor Blockers (ARBs)
 2) By Erythropoiesis-Stimulating Agents: Epoetin Alfa, Darbepoetin Alfa
 3) By Diuretics: Loop Diuretics, Thiazide Diuretics, Potassium-Sparing Diuretics
 4) By ACE Inhibitors: Lisinopril, Enalapril
 5) By Antidiabetic Agents: Metformin, Insulin
 6) By Other Drugs: Phosphate Binders, Vitamin D Analogues, Renin Inhibitors
 
 
 Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
 https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10076
 
 What defines the structure and scope of the nephrology drugs market?
 Nephrology drugs, also known as renal drugs, refer to medicines related to kidney care. These drugs are often related to high blood pressure and hypertension. It is used to attempt to enhance kidney function and to slow the disease down, preventing it from doing further harm to the body.
 
 About The Business Research Company:
 
 With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead. 
 
 Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
 
 Contact Us:
 
 The Business Research Company
 
 https://thebusinessresearchcompany.com/
 
 Europe: +44 207 1930 708
 
 Asia: +91 88972 63534
 
 Americas: +1 315 623 0293
 
 Email: info@tbrc.info
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company